Abbott Labs (NYSE: ABT ) and Mylan (NASDAQ: MYL ) gave investors reason to cheer today. Mylan bought up Abbott's established pharmaceuticals portfolio in non-emerging, ex-U.S. markets for $5.3 billion in an all-stock deal.
Was it a good idea for Mylan shareholders?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.
Everyone already knows about this deal
That's not a bad thing, but multibagger investments usually crop up when an investor recognizes true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.